Glatiramer acetate

Glatiramer acetate (also known as Copolymer 1, Cop-1), sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.

Glatiramer acetate
Clinical data
Trade namesCopaxone, Glatopa, Brabio
AHFS/Drugs.comMonograph
MedlinePlusa603016
License data
Pregnancy
category
  • AU: B1
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
  • none
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.248.824
Chemical and physical data
FormulaC25H45N5O13
Molar mass623.657 g·mol−1
 NY (what is this?)  (verify)

It is a mixture of random-sized peptides that are composed of the four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine. Myelin basic protein is the antigen in the myelin sheaths of the neurons that stimulates an autoimmune reaction in people with MS, so the peptide may work as a decoy for the attacking immune cells.

It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.